Browse News
Filter News
Found 5,612 articles
-
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
6/30/2022
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced interim data from the Company’s ongoing Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines.
-
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
6/30/2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2022.
-
Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
6/30/2022
Aimmune Therapeutics, Inc., will present new data on PALFORZIA® [Peanut Allergen (Arachis hypogaea) Power-dnfp] at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Prague, Czech Republic on July 1-3, 2022.
-
Significant Growth Foreseen by Oxytocin Market During 2020 - 2030
6/30/2022
Wilmington, Delaware, United States: Industry interest in the neuropeptide hormone oxytocin has surged on the back of the profound role it has in human evolution.
-
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
6/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.
-
MindMed, Scripps Research, Cingulate Therapeutics and the University of Pennsylvania discuss innovative treatments on the horizon for the treatment of anxiety disorder.
-
Cell MedX Corp: Letter to Shareholders from Mr. Dwayne Yaretz, CEO
6/27/2022
Having recently accepted the positions of CEO and Director of Cell MedX, I wanted to introduce myself to you, highlight the Company's most recent accomplishments and our vision for the future.
-
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
6/24/2022
Mirum Pharmaceuticals, Inc. presented data at the International Liver Congress™ of The European Association for the Study of the Liver in London, United Kingdom.
-
Systemic Scleroderma Treatment Market: Competitive Landscape Analysis with Forecast by 2031
6/24/2022
Wilmington, Delaware, United States: An autoimmune disorder that affects the skin and internal organs is called systemic scleroderma.
-
First BPH Treatment Procedures Performed in Canada with Minimally Invasive iTind Device
6/23/2022
Olympus, a global technology leader in designing and delivering innovative medical technology solutions, announced today the first commercial treatment of Benign Prostatic Hyperplasia (BPH) in Canada using the minimally invasive iTind™ procedure.
-
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
6/23/2022
VistaGen Therapeutics, Inc. (Nasdaq: VTGN), today reported its financial results for its fiscal year ended March 31, 2022 and provided a corporate update.
-
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
6/22/2022
Alpha Cognition Inc. today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).
-
Mesotherapy Market Segmentation and Forecast Analysis up to 2030
6/22/2022
Wilmington, Delaware, United States: Mesotherapy is a technique that is used to inject vitamins, enzymes, hormones, and plant extracts to rejuvenate and tighten skin as well as remove excess fat.
-
Acer Therapeutics and Relief Therapeutics announced the FDA has denied their NDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.
-
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
6/21/2022
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).
-
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
6/21/2022
Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
-
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1
6/21/2022
Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is exhibiting at the American College of Veterinary Internal Medicine (ACVIM) Forum, which takes place June 23 - 25, 2022 in Austin, TX.
-
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
-
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
6/17/2022
RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 3 to its Registration Statement on Form 20‑F with the U.S. Securities and Exchange Commission.
-
Transdermal Skin Patch Market Growth 2022-2028: Increasing Benefits Of Transdermal Medicine Over Oral And Swallowing Drugs That Cause Nausea And Vomiting
6/17/2022
The global transdermal skin patch market size was significantly robust in 2020 and is expected to register a steady revenue CAGR over the forecast period.